CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Hydroxychloroquine 200 Mg Oral TabletWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation

Correlated Drug Terms (4)

Name (Synonyms) Correlation
drug134 Azithromycin 500Mg Oral Tablet Wiki 0.71
drug131 Azithromycin 250 MG Wiki 0.71
drug543 Glucose tablets Wiki 0.71
drug1402 Tocilizumab Wiki 0.16

Correlated MeSH Terms (5)

Name (Synonyms) Correlation
D009369 Neoplasms, NIH 0.20
D011014 Pneumonia NIH 0.10
D055371 Acute Lung Injury NIH 0.08
D012127 Respiratory Distress Syndrome, Newborn NIH 0.08
D012128 Respiratory Distress Syndrome, Adult NIH 0.07

Correlated HPO Terms (2)

Name (Synonyms) Correlation
HP:0002664 Neoplasm HPO 0.21
HP:0002090 Pneumonia HPO 0.05

There are 2 clinical trials

Clinical Trials

1 Effectiveness of Hydroxychloroquine in Covid-19 Patients: A Single Centred Single-blind RCT Study

To find the effectiveness of hydroxychloroquine alone and adjuvant with azithromycin in mild to severe Covide-19 pneumonia patients admitted to Coronavirus cell/ward of Ayub Teaching hospital, Abbottabad Pakistan. A single centered, single-blind randomized control trial study.

NCT04328272 COVID19 Drug: Hydroxychloroquine 200 Mg Oral Tablet Drug: Azithromycin 500Mg Oral Tablet Dietary Supplement: Glucose tablets

Primary Outcomes

Description: National Early Warning Score equal to zero is when patients recovered clinically. Respiration 14-20breaths/minute, oxygen saturation percent greater than 96, (without breathing aid), systolic blood pressure 111-180 mmhg, pulse 60-90 beats.minute, alert consciousness and 35.1-38 degree Celsius body temperature.

Measure: National Early Warning Score equal to zero

Time: 3-5 Days

Secondary Outcomes

Description: below 3.0 miligram/Liter of blood sample

Measure: C-reactive proteins

Time: 3-5 Days

Description: 1000 -4800 lymphocytes in 1 microliter of blood

Measure: Lymphocyte Count

Time: 3-5days

Description: less than 250 ng/mL, or less than 0.4 mcg/mL of blood sample

Measure: d-dimers

Time: 3-5days

2 Hydroxychloroquine, Azithromycin in the Treatment of Covid-19 Pneumonia: A Randomized,Open-label,Controlled Clinical Trial

This study investigates the efficay and tolerance of 5-days course of hydroxychloroquine or hydroxychloroquine and azithromycin of patients with COVID-19 infection. The investigators will undertake a randomized, double-blind, controlled Trial in the region of Sousse Tunisia

NCT04405921 SARS-CoV-2 Pneumonia COVID-19 Drug: Hydroxychloroquine 200 Mg Oral Tablet Drug: Azithromycin 250 MG

Primary Outcomes

Description: Clinical recovery is defined as a complete resolution clinical signs appeared during the medical history and related to COVID-19.

Measure: Clinical recovery at day-14, from the start of treatment.

Time: 14 days

Secondary Outcomes

Description: RT-PCR will be realized in same laboratory

Measure: Viral Clearance via RT-PCR at day 5- 7-10 and day 14

Time: 5- 7-10 and day 14

Related HPO nodes (Using clinical trials)